Navigation Links
Defending against chemical acts of terrorism
Date:6/8/2012

Researchers may have found a way to protect us against otherwise deadly chemical attacks, such as the subway sarin incident in Tokyo that left thirteen people dead and thousands more injured or with temporary vision problems. The method is based on a new and improved version of a detoxifying enzyme produced naturally by our livers, according to the report in the April 2012 issue of Chemistry & Biology, a Cell Press publication.

"The sarin attack in Tokyo in 1995 demonstrated that both the raw materials and know-how of producing deadly nerve agents are available to people outside government or military institutions," said Moshe Goldsmith of the Weizmann Institute of Science in Israel. "We hope that our work would provide a prophylactic drug that will effectively protect the medical, police, and other teams that will have to act in a contaminated area following such an attack and would also provide these teams with a drug that could be administered on-site to intoxicated individuals to greatly improve their chances of survival."

Today, protection against nerve agents relies primarily on physical barriers such as gas masks and protective suits that can easily be breached, Goldsmith explained. Following exposure, people are treated with drugs that help with the symptoms but don't eliminate the nerve agent.

Goldsmith and the study's senior author Dan Tawfik hope to change this, relying on the principles of evolution to produce a more efficient version of an enzyme that occurs naturally in all of us. Known as paraoxonase 1 (PON1), this enzyme was originally named for its ability to assist in the breakdown of the insecticide paraoxon. It is also involved in drug metabolism and detoxification.

PON1 normally does counteract G-type nerve agents, including sarin, tabun, soman, and cyclosarin, but not well enough. Tawfik's lab specializes in a technique called "directed enzyme evolution,"in which they artificially introduce mutations into the gene encoding a target enzyme, in this case PON1. The mutated versions of the gene are then put back into bacteria, which produce the enzymes for testing. The goal was to end up with enzymes capable of detoxifying G-type nerve agents before those nerve agents could reach their target and cause harm. Those that passed the initial test went on to further rounds of evolution and testing.

After four rounds of evolution, the researchers obtained PON1 variants that worked up to 340 times better than those produced previously. Overall, the researches reported that the PON1 variants showed 40- to 3,400-fold higher efficiency than the normal enzyme in metabolizing the three most toxic G-type nerve agents.

These new and improved PON1 enzymes have become promising candidates for use as preventive and postexposure treatments in the event of a terrorist attack.

"We hope that our enzymes would be able to act together with currently available drugs to improve survival rates following intoxication," Goldsmith said. More broadly, the findings show the power of laboratory evolution to completely reshape existing enzymes for a variety of uses.


'/>"/>

Contact: Elisabeth (Lisa) Lyons
elyons@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Related biology technology :

1. Defending against chemical acts of terrorism
2. Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
3. Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager
4. MU researchers identify key plant immune response in fight against bacteria
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Nanosurgery and the fight against cancer: Major breakthrough at Polytechnique Montral
7. 3M Withdraws Blackmail Claims Against Harvey Boulter From New York Court
8. X-BODY BioSciences to Present Novel Methods of Selecting for Antibodies Against Targets on Live Cells at CHIs Protein Engineering Summit
9. The Italian Institute of Prophylaxis against Animal Diseases (IZS) to test effectiveness of BeesFree Inc.s Technology in Combating Colony Collapse Disorder
10. Elsevier and Federation of Biochemical Societies Launch New Journal: FEBS Open Bio
11. Bio architecture lab technology converts seaweed to renewable fuels and chemicals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Russian portfolio company of Maxwell Biotech Venture Fund (MBVF), today announced positive results of ... in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 is a new small molecule drug ... National Institutes of Health. Continue Reading ... ... ...
(Date:3/27/2017)... -- The new research portal will give visitors ... on Valero Energy , offering extensive market research on ... ... http://photos.prnewswire.com/prnh/20160330/349511LOGO) The latest trend gaining momentum ... today, even though touted as a green alternative to fossil ...
(Date:3/27/2017)... 27, 2017  Trovagene, Inc. (NASDAQ: TROV), a precision ... Officer, Bill Welch , will be presenting at ... 9:00 AM EDT at the Essex House in ... Chief Scientific Officer, Mark Erlander , Ph.D., will ... conference.   The presentation will be webcast live ...
(Date:3/24/2017)... -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative ... and patent-protected processes to develop and market advanced products ...  that it will present at the Needham Healthcare Conference ... H. "Pete" Petit, Chairman and CEO, Michael J. ... , EVP and Chief Commercialization Officer, and Mark ...
Breaking Biology Technology:
(Date:2/22/2017)... -- With the biometrics market to exceed $10 ... that innovative and agile startups must incorporate into ... changing competitive landscape: multifactor authentication (MFA), point-of-sale (PoS), ... "Companies can no longer afford to cut corners ... Pavlakis , Industry Analyst at ABI Research. "Pairing ...
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist ... as its new chief executive officer (CEO). Freischlag joins ... John D. McConnell , M.D., who last year ... at the Medical Center, after leading it since 2008. ... full scope of Wake Forest Baptist,s academic health system, ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
Breaking Biology News(10 mins):